Physician profile
Tracy Fabian
NPI 1801241161
$2,234.96
in general payments reported to CMS, 2019-2025
26 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.41 · 2020: $870 · 2021: $676 · 2022: $104 · 2023: $143 · 2024: $207 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $555.05 | 2019-2025 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $225.58 | 2020-2022 | |
| Esperion Therapeutics, INC. | $210.19 | 2020-2021 | |
| Lilly USA, LLC | $184.14 | 2020-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $175.29 | 2019-2024 | |
| Astellas Pharma US INC | $129.33 | 2020-2021 | |
| Novo Nordisk INC | $128.48 | 2020-2024 | Wegovy |
| Abbvie INC. | $67.57 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $63.41 | 2020-2023 | Gardasil 9 |
| Neurocrine Biosciences, INC. | $53.34 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $53.02 | 2020 | |
| Baxter Healthcare | $42.96 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $38.44 | 2020 | |
| Gilead Sciences, INC. | $37.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.79 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.57 | 2024-2025 | Evenity, Prolia, Otezla |
| Allergan, INC. | $31.37 | 2020 | |
| Daiichi Sankyo INC. | $31.13 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $26.03 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.40 | 2023 | Onpattro |
| Genentech USA, INC. | $18.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2020 | |
| Dexcom, INC. | $16.16 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.52 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Fabian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.